Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of “Hold” from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned a consensus rating of “Hold” from the twenty-two brokerages that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $124.15.

A number of research firms recently commented on ZBH. Wells Fargo & Company upped their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Raymond James reduced their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Stifel Nicolaus upped their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th.

Zimmer Biomet Trading Up 1.2 %

Shares of NYSE:ZBH opened at $104.89 on Monday. The company has a market cap of $20.88 billion, a P/E ratio of 23.57, a PEG ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet has a 1 year low of $97.69 and a 1 year high of $133.90. The stock’s fifty day moving average price is $105.86 and its 200-day moving average price is $107.46.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm earned $2.20 earnings per share. Sell-side analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s payout ratio is presently 21.57%.

Institutional Investors Weigh In On Zimmer Biomet

Several institutional investors have recently modified their holdings of the stock. Dodge & Cox raised its holdings in shares of Zimmer Biomet by 12.0% in the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider’s stock worth $2,019,480,000 after buying an additional 2,044,645 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Zimmer Biomet by 1.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider’s stock valued at $1,559,147,000 after acquiring an additional 176,337 shares during the period. Geode Capital Management LLC boosted its position in shares of Zimmer Biomet by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after purchasing an additional 125,852 shares in the last quarter. Van ECK Associates Corp boosted its position in shares of Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock worth $417,814,000 after purchasing an additional 218,688 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in shares of Zimmer Biomet by 398.7% in the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider’s stock worth $369,469,000 after purchasing an additional 2,796,372 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.